Publicacións en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (23)

2024

  1. Targeted Treatment against Cancer Stem Cells in Colorectal Cancer

    International Journal of Molecular Sciences, Vol. 25, Núm. 11

2022

  1. Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression

    Oncogene, Vol. 41, Núm. 13, pp. 1835-1850

  2. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma

    Gut, Vol. 72, Núm. 2, pp. 345-359

  3. Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma

    Journal of Cutaneous Pathology, Vol. 49, Núm. 5, pp. 472-481

2021

  1. Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis

    Cancer Chemotherapy and Pharmacology, Vol. 87, Núm. 1, pp. 113-124

  2. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

    The Lancet Oncology, Vol. 22, Núm. 2, pp. 212-222

  3. Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial

    European Journal of Cancer, Vol. 148, pp. 382-394

  4. Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials

    Cancer Medicine, Vol. 10, Núm. 17, pp. 5748-5756

2020

  1. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment

    Lung Cancer, Vol. 150, pp. 90-96

  2. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer

    European Urology, Vol. 78, Núm. 5, pp. 652-656

  3. Circulating Tumor Cells Characterization Revealed TIMP1 as a Potential Therapeutic Target in Ovarian Cancer

    Cells, Vol. 9, Núm. 5

  4. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

    The Lancet Oncology, Vol. 21, Núm. 5, pp. 645-654

  5. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

    The Lancet Oncology, Vol. 21, Núm. 11, pp. 1413-1422

2019

  1. Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion

    European Journal of Cancer, Vol. 120, pp. 54-64

  2. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study)

    Oncologist, Vol. 24, Núm. 4, pp. 491-497

  3. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy

    Annals of Oncology, Vol. 30, Núm. 3, pp. 439-446

2018

  1. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: A Meta-analysis

    Journal of the National Cancer Institute, Vol. 110, Núm. 6, pp. 560-567

  2. Multicenter phase II study of lurbinectedin in BRCAMutated and unselected metastatic advanced breast cancer and biomarker assessment substudy

    Journal of Clinical Oncology, Vol. 36, Núm. 31, pp. 3134-3143

2016

  1. Anti-tumor activity of PM01183 (lurbinectedin) in BRCA1/2-associated metastatic breast cancer patients: results of a single-agent phase II trial

    Annals of Oncology, Vol. 27, pp. vi68

2014

  1. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

    Cancer, Vol. 120, Núm. 10, pp. 1453-1461